Last update: Dec. 24, 2018

Deferoxamine

Very Low Risk for breastfeeding


Safe. Compatible.
Not risky for breastfeeding or infant.

An iron and aluminum chelator that increases the elimination of both metals from the body.
Used over short periods to treat acute poisoning from these metals and, over longer periods, to treat chronic iron overload, hemochromatosis, hemosiderosis from repeated transfusions due to thalassemia major or other chronic anemias.
Administered subcutaneously, intramuscularly and intravenously.

At least three cases have been reported of infants of mothers suffering from thalassemia major who were treated with deferoxamine and breast-fed without any problems for the infant or in the iron metabolism of the milk (Pafumi 2000, Surbek 1998).

Its low percentage of protein binding makes its excretion in milk possible, but its practically zero oral bioavailability prevents its transfer to the infant’s plasma via ingested breast milk, except in premature babies and the immediate neonatal period in which there may be increased intestinal permeability.

According to expert authors, the possible presence of deferoxamine in breast milk is unlikely to have harmful effects in the infant (Briggs 2017, Pafumi 2000, Jensen 1995) so there is no reason to stop breastfeeding during treatment.
It may be advisable to control the infant’s serum iron levels.

Alternatives

We do not have alternatives for Deferoxamine since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Deferoxamine is also known as


Deferoxamine in other languages or writings:

Tradenames

Main tradenames from several countries containing Deferoxamine in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. < 2 %
Molecular weight 659 daltons
Protein Binding < 10 %
VD 1,33 l/Kg
pKa 8,39 -
Tmax 0,5 hours
T1/2 2 - 6 hours

References

  1. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. 11th edition (acces on line) 2017
  2. Noridem. Deferoxamine. Drug Summary. 2012 Full text (in our servers)
  3. AEMPS. Deferoxamina. Ficha técnica. 2011 Full text (in our servers)
  4. Pafumi C, Zizza G, Caruso S, Todaro AM, Pernicone G, Bandiera S, Farina M, Russo A. Pregnancy outcome of a transfusion-dependent thalassemic woman. Ann Hematol. 2000 Abstract
  5. Surbek DV, Glanzmann R, Holzgreve W. Pregnancy and homozygous beta thalassemia major. Br J Obstet Gynaecol. 1999 Abstract
  6. Surbek DV, Glanzmann R, Nars PW, Holzgreve W. Pregnancy and lactation in homozygous beta-thalassemia major. J Perinat Med. 1998 Abstract
  7. Jensen CE, Tuck SM, Wonke B. Fertility in beta thalassaemia major: a report of 16 pregnancies, preconceptual evaluation and a review of the literature. Br J Obstet Gynaecol. 1995 Abstract

Total visits

2,540

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM